Last reviewed · How we verify
:Anti-CD22-CAR
Chimeric antigen receptor targeting CD22
Chimeric antigen receptor targeting CD22 Used for B-cell malignancies.
At a glance
| Generic name | :Anti-CD22-CAR |
|---|---|
| Sponsor | Kecellitics Biotech Company Ltd |
| Drug class | CAR-T cell therapy |
| Target | CD22 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
This CAR-T cell therapy targets CD22, a protein expressed on the surface of B cells, to selectively kill cancer cells.
Approved indications
- B-cell malignancies
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
Key clinical trials
- Co-administration of CART22-65s and huCART19 for B-ALL (PHASE1, PHASE2)
- Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (PHASE1)
- A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies (PHASE1, PHASE2)
- Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (PHASE1)
- CD22 Redirected Autologous T Cells for ALL (PHASE1)
- Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant (PHASE1)
- CART22 Alone or in Combination With huCART19 for ALL (PHASE1)
- Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- :Anti-CD22-CAR CI brief — competitive landscape report
- :Anti-CD22-CAR updates RSS · CI watch RSS
- Kecellitics Biotech Company Ltd portfolio CI